| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | YBX1; NSEP1; YB1; Nuclease-sensitive element-binding protein 1; CCAAT-binding transcription factor I subunit A; CBF-A; DNA-binding protein B; DBPB; Enhancer factor I subunit A; EFI-A; Y-box transcription factor; Y-box-binding protein 1; YB- |
| Entrez GeneID | 4904 |
| WB Predicted band size | Calculated MW: 36 kDa; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human YB1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于YB1抗体的3篇参考文献示例(内容为模拟概括，非真实文献)：
---
1. **文献名称**：《YB1蛋白在乳腺癌中的表达及其临床意义》
**作者**：Smith A, et al.
**摘要**：本研究通过免疫组化技术，利用特异性YB1抗体分析乳腺癌组织中YB1蛋白的表达水平，发现高表达YB1与肿瘤转移和患者预后不良显著相关，提示YB1可能作为乳腺癌的生物标志物。
2. **文献名称**：《抗YB1单克隆抗体的制备及其在结肠癌诊断中的应用》
**作者**：Zhang L, et al.
**摘要**：研究团队成功制备高亲和力的抗YB1单克隆抗体，验证了其在结肠癌细胞系和组织中的特异性识别能力，并证明该抗体可用于液体活检中循环肿瘤细胞的检测，为癌症早期诊断提供新工具。
3. **文献名称**：《靶向YB1的抗体抑制胶质瘤细胞化疗耐药性的机制研究》
**作者**：Wang Y, et al.
**摘要**：通过抗YB1抗体阻断YB1蛋白功能，发现其可下调胶质瘤细胞中多药耐药基因(如MDR1)的表达，增强化疗药物敏感性，为克服肿瘤耐药性提供了潜在治疗策略。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“YB1 antibody”或“Y-box binding protein 1 antibody”。
The YB1 antibody targets Y-box binding protein 1 (YB1), a multifunctional member of the cold shock protein family encoded by the *YBX1* gene. Initially identified as a DNA/RNA-binding protein, YB1 regulates transcription, mRNA stability, and translation by interacting with nucleic acids through its conserved cold shock domain. Structurally, YB1 comprises an N-terminal domain involved in protein oligomerization, a central cold shock domain for nucleic acid binding, and a C-terminal domain rich in charged residues.
YB1 is ubiquitously expressed and plays critical roles in cellular stress responses, proliferation, and differentiation. It is implicated in cancer progression, where its overexpression correlates with tumor aggressiveness, metastasis, and chemoresistance in various cancers, including breast, colorectal, and glioblastoma. YB1 regulates oncogenic pathways (e.g., PI3K/AKT, MAPK) and promotes epithelial-mesenchymal transition (EMT). Additionally, it influences the tumor microenvironment by modulating cytokine secretion.
Antibodies against YB1 are essential tools in research, enabling detection of its expression and localization via techniques like Western blot, immunohistochemistry, and immunofluorescence. Specific clones (e.g., D299. EPR13934) or phospho-specific antibodies (e.g., targeting Ser102) help dissect YB1's functional states. Studies also explore YB1 as a therapeutic target, given its dual role in tumorigenesis and potential to enhance chemotherapy efficacy when inhibited. Its pleiotropic functions and disease relevance continue to drive interest in YB1-focused biomedical research.
×
